SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549

FORM 10-Q

(Mark One)

X QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 1997

or
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to
Commission File Number 0-11576
Harris & Harris Group, Inc.
(Exact name of registrant as specified in its charter)
New York 13-3119827
(State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.)
One Rockefeller Plaza Suite 1430 New York, New York 10020
(Address of principal executive offices) (212) 332-3600
(Registrant's telephone number, including area code)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes X No Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date. The number of shares of common stock, par value \$.01 per share, outstanding on May 1, 1997 was 10,442,682.
1
Harris & Harris Group, Inc. Form 10Q, March 31, 1997
<table> <caption> TABLE OF CONTENTS</caption></table>
<\$>
Page Number PART I. FINANCIAL INFORMATION
Item 1. Financial Statements
Statements of Assets and Liabilities 4
Statements of Operations 5
Statements of Cash Flows 6

Statements of Changes in Net Assets				
Schedule of Investments 8				
Notes to Financial Statements				
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations				
Financial Condition				
Results of Operations				
Liquidity and Capital Resources				
Risks				
PART II OTHER INFORMATION				
Item 1. Legal Proceedings				
Item 2. Changes in Securities				
Item 3. Defaults Upon Senior Securities				
Item 4. Submission of Matters to a Vote of Security Holders 26				
Item 5. Other Information				
Item 6. Exhibits and Reports on Form 8-K				
Exhibit Index				
Signature				
2				
Harris & Harris Group, Inc.				

Harris & Harris Group, Inc. Form 10-Q, March 31, 1997

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

The information furnished in the accompanying financial statements reflects all adjustments that are, in the opinion of management, necessary for a fair presentation of the results for the interim period presented.

On June 30, 1994, the Company's shareholders approved a proposal to allow the Company to make an election to become a Business Development Company ("BDC") under the Investment Company Act of 1940, as amended. The Company made such election on July 26, 1995. Certain information and disclosures normally included in the financial statements in accordance with Generally Accepted Accounting Principles have been condensed or omitted as permitted by Regulation S-X and Regulation S-K. It is suggested that the accompanying financial statements be read in conjunction with the audited financial statements and notes thereto for the year ended December 31, 1996 contained in the Company's 1996 Annual Report.

3

</TABLE> <TABLE> <CAPTION>

STATEMENTS OF ASSETS AND LIABILITIES

ASSETS





March 31, 1997 December 31, 1996 (Unaudited) (Audited)				
Investments, at value (See accompanying schedule of investments and notes). \$ 33,703,525 \$ 35,648,682 Cash and cash equivalents. 159,122 155,440 Receivable from brokers. 25,374 0 Interest receivable. 81,518 198,342 Taxes receivable (Note 5). 2,103,294 2,119,492 Prepaid expenses 60,525 81,501 Other assets 231,919 351,833				
Total assets				
LIABILITIES & NET ASSETS				
Accounts payable and accrued liabilities \$ 346,029				
Total liabilities 2,094,962 2,622,687 Commitments and contingencies (Note 6)				
Net assets				
Net assets are comprised of: Preferred stock, \$0.10 par value, 2,000,000 shares authorized; none issued \$ 0 \$ 0 Common stock, \$0.01 par value, 25,000,000 shares authorized; 10,442,682 issued and outstanding at 3/31/97 and 12/31/96 104,427 Additional paid in capital 15,850,576 Accumulated net realized income 15,636,467 15,606,009 Accumulated unrealized appreciation of investments, net of deferred tax liability of \$1,384,519 at 3/31/97 and \$2,295,998 at 12/31/96 2,678,845 4,371,591				
Net assets				
Shares outstanding				
Net asset value per outstanding share \$ 3.28 \$ 3.44				

| The accompanying notes are an integral part of these financial statements. |
| 4 |
| |
| STATEMENTS OF OPERATIONS |
| (Unaudited) |
| ~~Three Three Months Ended March 31, 1997 March 31, 1996~~ |
| Investment income: Interest from: Fixed-income securities |
| Expenses: Salaries and benefits |
440,324

Salaries and benefits

396,631

Administration and operations 98,327 122,212 Professional fees 88,097 126,905 Depreciation 15,000 10,000 Rent 39,497 38,346 Directors' fees and expenses 35,848 12,400 Custodian fees 3,506 3,116
Total expenses
Operating loss before income taxes (573,443) (443,286) Income tax benefit (Note 5)
Net operating loss (374,562) (289,156)
Net realized gain on investments: Realized gain on sale of investments 623,108 64,420
Total realized gain
Net realized gain on investments
Net realized income (loss)
Net (decrease) increase in unrealized appreciation on investments: Decrease as a result of investment sales
Net (decrease) increase in net assets from operations: Total \$ (1,662,288) \$ 547,793
Per outstanding share

| The accompanying notes are an integral part of these financial statements. |
| |
| STATEMENTS OF CASH FLOWS |
| (Unaudited) ~~C> Three Three Months Ended March 31, 1997 March 31, 1996~~ |
| Cash flows provided by (used in) operating activities: Net (decrease) increase in net assets resulting from operations \$ (1,662,288) \$ 547,793 Adjustments to reconcile (decrease) increase in net assets from operations to net cash provided by (used in) operating activities: Net realized and unrealized loss (gain) on investments |

Receivable from brokers (25,374) (2,805,585) Prepaid expenses 20,976 15,849 Interest receivable 116,824 (8,012) Taxes receivable 16,197 (134,593) Other assets 107,762 (27,400) Accounts payable and accrued liabilities (28,297) 20,671 Payable to brokers 411,354 0 Deferred rent (2,313) 0 Purchase of fixed assets (2,847) (24,697)
Net cash provided by (used in) operating activities
Cash provided by (used in) investing activities: Net sale of short-term investments and marketable securities 1,709,625 5,234,633 Investment in private placements (1,745,585) (1,943,302)
Net cash (used in) provided by investing activities (35,960) 3,291,331
Cash flows provided by financing activities: Proceeds from exercise of stock options 0 87,500
Net cash provided by financing activities 0 87,500
Net increase in cash and cash equivalents:
Cash and cash equivalents at beginning of the period 155,440 364,354 Cash and cash equivalents at end of the period 159,122 478,410
Net increase in cash and cash equivalents \$ 3,682 \$ 114,056
Supplemental disclosures of cash flow information: Income taxes paid

| The accompanying notes are an integral part of these financial statements. |
| 6 |
| |
| STATEMENTS OF CHANGES IN NET ASSETS |
| |
| (Unaudited) ~~C> Three Months Ended March 31, 1997 March 31, 1996~~ |
| ~~Three Three Months Ended Months Ended~~ |
| Three Three Months Ended Months Ended March 31, 1997 March 31, 1996 Changes in net assets from operations: Net operating loss |
| Three Three Months Ended Months Ended March 31, 1997 March 31, 1996 Changes in net assets from operations: Net operating loss |
| Three Three Months Ended Months Ended March 31, 1997 March 31, 1996 Changes in net assets from operations: Net operating loss \$ (374,562) \$ (289,156) Net realized gain on investments 405,020 41,873 Net decrease in unrealized appreciation on investments as a result of sales (1,147,190) 0 Net (decrease) increase in unrealized appreciation on investments held (545,556) 795,076 Net (decrease) increase in net |

and common stock transactions 0 72,188
Net increase in net assets resulting from capital stock transactions 0 159,688
Net (decrease) increase in net assets (1,662,288) 707,481
Net assets:
Beginning of period
End of period \$ 34,270,315 \$ 37,269,390

| The accompanying notes are an integral part of these financial statements. |
| 7 |
| |
| SCHEDULE OF INVESTMENTS MARCH 31, 1997 |
| (Unaudited) |
| |
| Investments in Unaffiliated Companies (9)(13)(14) 14.1% of total investments |
| Publicly Traded Portfolio (common stock unless noted otherwise) 6.2% of total investments |
| Oil and Gas Related CORDEX Petroleums Inc. (1) Argentine oil and gas exploration Class A Common Stock(C) 4,052,080 \$ 324,156 |
| Biotechnology and Healthcare Related ENDOCare, Inc.(1)(2)(4) (C) 150,000 609,375 Fuisz Technologies, Inc.(1)(4) (C) 70,000 411,250 Keravision, Inc.(1)(4) (C) 25,000 253,125 Magellan Health Services,Inc.(1)(6)(4)(C) 20,000 492,500 |
| Total Publicly Traded Portfolio (cost: \$2,230,212) \$ 2,090,406 |
| Private Placement Portfolio (Illiquid) 7.9% of total investments |
| Exponential Business Development Company (1)(2)(5) Venture capital partnership focused on early stage companies Limited partnership interest (A) 0 \$ 25,000 Micracor, Inc. (1)(2) Designs and manufactures advanced solid state photonic systems Convertible Note (D) \$ 103,000 40,000 Princeton Video Image, Inc. (1)(2) (5)(7)(8) Real time sports and entertainment advertising 3.4% of fully diluted equity Common Stock (B) 68,400 Warrants at \$2.25 expiring 8/25/97 . (D) 6,700 2,613,425 |
| Total Private Placement Portfolio (cost: \$771,000) \$ 2,678,425 |

```
Total Investments in
  Unaffiliated Companies (cost: $3,001,212).....$ 4,768,831
</TABLE>
     The accompanying notes are an integral part of this schedule.
<TABLE>
<CAPTION>
           SCHEDULE OF INVESTMENTS MARCH 31, 1997
                   (Unaudited)
<S>
                          <C>
                                      <C>
                                                  <C>
                        Method of
                                     Shares/
                        Valuation (3) Principal
                                                   Value
Private Placement Portfolio in Non-Controlled Affiliates (9)(14)(Illiquid) --
33.1% of total investments
Dynecology Incorporated (1)(2)(5)(7) --
  Develops various
  environmental intellectual properties --
  Option expiring
  12/13/98 to purchase at $15 per share
  135,000 shares of Common Stock equaling
  18.1% of fully diluted equity. . . . . . (D)
                                                      $ 35,000
Gel Sciences, Inc. (1)(2)(7) --
  Develops engineered response gels
  for controlled release systems --
  10.3% of fully diluted equity
  Warrants at $1.65 expiring 02/01/00...(D)
                                                  27,766
  Common Stock . . . . . . . . . (B)
                                           171,172
  Series A Preferred Stock . . . . . . . (D)
                                             135,178
  Series A-1 Preferred Stock . . . . . . . (D)
                                               57,607
  Series B Convertible Preferred Stock . . .(B)
                                                  397,409
  Series C Convertible Preferred Stock . . .(B)
                                                  101,515 2,353,921
Genomica Corporation (1)(2)(7)(10) --
  Develops software that enables the
  study of complex genetic diseases
  18.1% of fully diluted equity
  Common Stock . . . . . . . . . . . . . . . . . . (A)
                                            199,800
  Series A Voting Convertible
  Preferred Stock. . . . . . . . . . . . . (A)
                                         1,660,200 1,000,304
Harber Brothers Productions, Inc. (1)(2)(7) --
  Finances, produces and markets media
  products that combine entertainment, music,
  learning and interactivity --
  21.5% of fully diluted equity
  Series A Voting Convertible
  Preferred Stock .....(D)
                                          967,500
  Convertible Note . . . . . . . . . (D)
                                          $ 250,000
                                                           1
Highline Capital Management, LLC. (2)(7) --
  Organizes and manages
  offshore investment vehicles --
                                                      500,000
  24.9% of fully diluted equity. . . . . . (A)
Highline Offshore Advisors, LLC. (1)(2)(4) --
  Organizes and manages investment
  partnerships --
  24.9% of fully diluted equity. . . . . . (A)
                                                       500,000
Nanophase Technologies Corporation (1)(2)
  (5)(7) -- Manufactures and markets
  inorganic crystals of nanometric dimensions
  6.9% of fully diluted equity
  Series D Convertible Preferred Stock. . . (B)
                                                 1,162,204 2,614,959
NeuroMetrix, Inc. (1)(2)(5)(7) -- Developing
  a device for diabetics to monitor their
  blood glucose --
  30% of fully diluted equity
  Series A Convertible Preferred Stock. . . (A)
                                                  125,000
  Warrants at $1.60 expiring 6/2/97... (A)
                                                 175,000
                                                            210,000
PHZ Capital Partners Limited Partnership
```

```
(1)(2)(5) Organizes and manages investment
  partnerships --
  20.0% of fully diluted equity
  Limited partnership interest . . . . . . (B)
                                                   1,000,000
  One year 8% note due 9/22/97 . . . . . . (A) $ 500,000
                                                           500,000
PureSpeech, Inc. (1)(2)(7) -- Develops and
  markets innovative speech recognition
  technology -- 7.3% of fully diluted equity
  Series A Convertible Preferred Stock . . .(D)
                                                 190,476
                                                             166,667
Questech Corporation (1)(2)(5)(11) --
  Manufactures and markets
  proprietary decorative tiles and signs --
  15.4% of fully diluted equity
  Common Stock . . . . . . . . . . . (D)
                                           565,792 2,263,168
  Warrants at $4.00 expiring 11/28/01...(A)
                                                166,667
                                                               167
Total Private Placement Portfolio
  in Non-Controlled Affiliates (cost: $10,131,823) . . . . . $11,144,187
</TABLE>
    The accompanying notes are an integral part of this schedule.
<TABLE>
<CAPTION>
          SCHEDULE OF INVESTMENTS MARCH 31, 1997
                  (Unaudited)
<S>
                          <C>
                                      <C>
                                                  <C>
                        Method of Shares/
                        Valuation (3) Principal
                                                   Value
Private Placement Portfolio in Controlled Affiliates (9)(14) (Illiquid) --
17.6% of total investments
BioSupplyNet, Inc. (1)(2)(4)(7)(12)--
  Expands commercially the print and
  World Wide Web product directories
  developed by Cold Spring Harbor
  Laboratory Press --
  34.5% fully diluted equity
  Series A Voting Convertible
  Preferred Stock. . . . . . . . . (A)
                                         575,000 $ 575,000
MultiTarget, Inc. (1)(2)(7) -- Developing
  intellectual property
  related to localized treatment of cancer
  37.8% of fully diluted equity
  Series A Convertible Preferred Stock. . .(A)
                                                 375,000
                                                             106,396
nFX Corporation (1)(2) -- Develops
  neural-network software --
  37.4% of fully diluted equity
  Series A Voting Convertible
  Preferred Stock . . . . . . . . . (D)
                                       1,294,288
                                                     996,740
  Series B Non-Voting Convertible
  689,920 1,539,980
  Convertible Note. . . . . . . . . . . . . . . . . (A)
                                        $ 100,000
                                                      100,000
PowerVoice Technologies, Inc. (1)(2)(7) --
  Exploits innovative distributed computing
  technology for use in small business
  telephone systems --
  27% of fully diluted equity
  Series A Convertible Preferred Stock. . (B)
                                                 500,000
  Series C Convertible Preferred Stock. . (B)
                                                240,793 2,615,000
Total Private Placement Portfolio
  in Controlled Affiliates (cost: $4,668,116) . . . . . . $ 5,933,116
U.S. Government Obligations -- 35.2% of total investments
```

U.S. Treasury Note dated 3/01/93 due date

02/28/98 5.125% rate (H) \$ 5,000,000 \$ 4,957,050				
U.S. Treasury Bill dated 10/24/96 due date				
04/24/97 5.0% yield (K) \$ 1,015,000 998,492				
U.S. Treasury Bill dated 05/30/96 due date				
05/29/97 5.3% yield (K) \$ 915,000 904,014				
U.S. Treasury Bill dated 12/12/96 due date				
06/12/97 5.3% yield (K) \$ 1,000,000 974,975				
U.S. Treasury Bill dated 10/24/96 due date				
08/14/97 5.4% yield (K) \$ 810,000 792,984				
U.S. Treasury Bill dated 03/13/97 due date				
09/11/97 5.5% yield (K) \$ 1,740,000 1,695,693				
U.S. Treasure Bill dated 11/14/96 due date				
11/13/97 5.7% yield (K) \$ 1,590,000 \$ 1,534,183				
Total Investments in U.S. Government Obligations				
(cost: \$11,839,010) \$ 11,857,391				
Total Investments 100% (cost: \$29,640,161) \$33,703,525				

The accompanying notes are an integral part of this schedule.

SCHEDULE OF INVESTMENTS MARCH 31, 1997 (Unaudited)

Notes to Schedule of Investments:

- (1) Represents a non-income producing security. Equity investments that have not paid dividends within the last twelve months are considered to be non-income producing.
- (2) Legal restrictions on sale of investment.
- (3) See Footnote to Schedule of Investments for a description of the Method of Valuation A to L.
- (4) These investments were made during 1997. Accordingly, the amounts shown on the schedule represent the gross additions in 1997.
- (5) No activity occurred in these investments during the three months ended March 31, 1997.
- (6) Formerly named National Mentor Holding Corp., Magellan Health Services, Inc. was later acquired by Charter Medical Corporation, which subsequently changed its name to Magellan Health Services, Inc.
- (7) These investments are development stage companies. A development stage company is defined as a company that is devoting substantially all of its efforts to establishing a new business, and either has not yet commenced its planned principal operations or has commenced such operations but has not realized significant revenue from them.
- (8) Formerly named Princeton Electronic Billboard, Inc.
- (9) Investments in unaffiliated companies consist of investments where Harris & Harris Group, Inc. (the "Company") owns less than 5 percent of the investee company. Investments in non-controlled affiliated companies consist of investments where the Company owns more than 5 percent but less than 25 percent of the investee company. Investments in controlled affiliated companies consist of investments where the Company owns more than 25 percent of the investee company.
- (10) Genomica Corporation was cofounded by the Company, Cold Spring Harbor Laboratory and Falcon Technology Partners, LP. Mr. G. Morgan Browne serves on the Board of the Company and is Administrative Director of Cold Spring Harbor Laboratory.
- (11) Formerly named Intaglio, Ltd.
- (12) BioSupplyNet, Inc. was cofounded by the Company, Cold Spring Harbor Laboratory and other investors. Mr. G. Morgan Browne serves on the Board of Directors and is Administrative Director of Cold Spring Harbor Laboratory.
- (13) The aggregate cost for federal income tax purposes of investments in unaffiliated companies is \$3,108,889. The gross unrealized appreciation based on tax cost for these securities is \$2,054,800. The gross unrealized depreciation on the cost for these securities is \$394,858.
- (14) The percentage ownership of each investee disclosed in the Schedule of

Investments expresses the potential common equity interest in each such investee. The calculated percentage represents the amount of issuer's common stock the Company owns or can acquire as a percentage of the issuer's total outstanding common stock plus common shares reserved for issued and outstanding warrants, convertible securities and stock option grants.

The accompanying notes are an integral part of this schedule.

11

FOOTNOTE TO SCHEDULE OF INVESTMENTS

ASSET VALUATION POLICY GUIDELINES

The Company's investments can be classified into five broad categories for valuation purposes:

- 1) EQUITY-RELATED SECURITIES
- 2) INVESTMENTS IN INTELLECTUAL PROPERTY OR PATENTS OR RESEARCH AND DEVELOPMENT IN TECHNOLOGY OR PRODUCT DEVELOPMENT
- 3) LONG-TERM FIXED-INCOME SECURITIES
- 4) SHORT-TERM FIXED-INCOME INVESTMENTS
- 5) ALL OTHER INVESTMENTS

The Investment Company Act of 1940 (the "1940 Act") requires periodic valuation of each investment in the Company's portfolio to determine net asset value. Under the 1940 Act, unrestricted securities with readily available market quotations are to be valued at the current market value; all other assets must be valued at "fair value" as determined in good faith by or under the direction of the Board of Directors.

The Company's Board of Directors is responsible for 1) determining overall valuation guidelines and 2) ensuring the valuation of investments within the prescribed guidelines.

The Company's Investment and Valuation Committee, comprised of at least three or more Board members, is responsible for reviewing and approving the valuation of the Company's assets within the guidelines established by the Board of Directors.

Fair value is generally defined as the amount that an investment could be sold for in an orderly disposition over a reasonable time. Generally, to increase objectivity in valuing the assets of the Company, external measures of value, such as public markets or third-party transactions, are utilized whenever possible. Valuation is not based on long-term work-out value, nor immediate liquidation value, nor incremental value for potential changes that may take place in the future.

Valuation assumes that, in the ordinary course of its business, the Company will eventually sell its investment.

The Company's valuation policy with respect to the five broad investment categories is as follows:

1

EQUITY-RELATED SECURITIES

Equity-related securities are carried at fair value using one or more of the following basic methods of valuation:

A. Cost: The cost method is based on the original cost to the Company. This method is generally used in the early stages of a company's development until significant positive or negative events occur subsequent to the date of the original investment that dictate a change to another valuation method. Some examples of such events are: 1) a major recapitalization; 2) a major refinancing; 3) a significant third-party transaction; 4) the development

of a meaningful public market for the company's common stock; 5) significant positive or negative changes in the company's business.

- B. Private Market: The private market method uses actual third-party transactions in the company's securities as a basis for valuation, using actual, executed, historical transactions in the company's securities by responsible third parties. The private market method may also use, where applicable, unconditional firm offers by responsible third parties as a basis for valuation.
- C. Public Market: The public market method is used when there is an established public market for the class of the company's securities held by the Company. The Company discounts market value for securities that are subject to significant legal, contractual or practical restrictions, including large blocks in relation to trading volume. Other securities, for which market quotations are readily available, are carried at market value as of the time of valuation.

Market value for securities traded on securities exchanges or on the NASDAQ National Market System is the last reported sales price on the day of valuation. For other securities traded in the over-the-counter market and listed securities for which no sale was reported on that day, market value is the mean of the closing bid price and asked price on that day.

This method is the preferred method of valuation when there is an established public market for a company's securities, as that market provides the most objective basis for valuation.

D. Analytical Method: The analytical method is generally used to value an investment position when there is no established public or private market in the company's securities or when the factual information available to the Company dictates that an investment should no longer be valued under either the cost or private market method. This valuation method is inherently imprecise and ultimately the result of reconciling the judgments of the Company's Investment and Valuation Committee members, based on the data available to them. The resulting valuation, although stated as a precise number, is necessarily within a range of values that vary depending upon the significance attributed to the various factors being considered. Some of the factors considered may include the financial condition and operating results of the company, the long-term potential of the business of the company, the values of similar securities issued by companies in similar businesses, the proportion of the company's securities owned by the Company and the nature of any rights to require the company to register restricted securities under applicable securities laws.

13

INVESTMENTS IN INTELLECTUAL PROPERTY OR PATENTS OR RESEARCH AND DEVELOPMENT IN TECHNOLOGY OR PRODUCT DEVELOPMENT

Such investments are carried at fair value using the following basic methods of valuation:

- E. Cost: The cost method is based on the original cost to the Company. Such method is generally used in the early stages of commercializing or developing intellectual property or patents or research and development in technology or product development until significant positive or adverse events occur subsequent to the date of the original investment that dictate a change to another valuation method.
- F. Private Market: The private market method uses actual third-party investments in intellectual property or patents or research and development in technology or product development as a basis for valuation, using actual executed historical transactions by responsible third parties. The private market method may also use, where applicable, unconditional firm offers by responsible third parties as a basis for valuation.
- G. Analytical Method: The analytical method is used to value an investment after analysis of the best available outside information where the factual information available to the Company dictates that an investment should no longer be valued under either the cost or private market method. This valuation method is inherently imprecise and ultimately the result of reconciling the judgments of the Company's Investment and Valuation Committee

members. The resulting valuation, although stated as a precise number, is necessarily within a range of values that vary depending upon the significance attributed to the various factors being considered. Some of the factors considered may include the results of research and development, product development progress, commercial prospects, term of patent and projected markets.

LONG-TERM FIXED-INCOME SECURITIES

H. Fixed-Income Securities for which market quotations are readily available are carried at market value as of the time of valuation using the most recent bid quotations when available.

Securities for which market quotations are not readily available are carried at fair value using one or more of the following basic methods of valuation:

- I. Fixed-Income Securities are valued by independent pricing services that provide market quotations based primarily on quotations from dealers and brokers, market transactions, and other sources.
- J. Other Fixed-Income Securities that are not readily marketable are valued at fair value by the Investment and Valuation Committee.

SHORT-TERM FIXED-INCOME INVESTMENTS

K. Short-Term Fixed-Income Investments are valued at market value at the time of valuation. Short-term debt with remaining maturity of 60 days or less is valued at amortized cost.

ALL OTHER INVESTMENTS

L. All Other Investments are reported at fair value as determined in good faith by the Investment and Valuation Committee.

14

The reported values of securities for which market quotations are not readily available and for other assets reflect the Investment and Valuation Committee's judgment of fair values as of the valuation date using the outlined basic methods of valuation. They do not necessarily represent an amount of money that would be realized if the securities had to be sold in an immediate liquidation. The Company makes many of its portfolio investments with the view of holding them for a number of years, and the reported value of such investments may be considered in terms of disposition over a period of time. Thus valuations as of any particular date are not necessarily indicative of amounts that may ultimately be realized as a result of future sales or other dispositions of investments held.

15

NOTES TO FINANCIAL STATEMENTS

(Unaudited)

NOTE 1. THE COMPANY

Harris & Harris Group, Inc. (the "Company") is a venture capital investment company operating as a business development company ("BDC") under the Investment Company Act of 1940 ("1940 Act"). A BDC is a specialized type of investment company under the 1940 Act. The Company operates as an internally managed investment company whereby its officers and employees, under the general supervision of its Board of Directors, conduct its operations.

The Company elected to become a BDC on July 26, 1995, after receiving the necessary approvals. From July 31, 1992 until the election of BDC status, the Company operated as a closed-end, non-diversified, investment company under the 1940 Act. Upon commencement of operations as an investment company, the Company revalued all of its assets and liabilities at fair value as defined in the 1940 Act. Prior to such time, the Company was registered and filed under

the reporting requirements of the Securities and Exchange Act of 1934 as an operating company and, while an operating company, operated directly and through subsidiaries.

NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The following is a summary of significant accounting policies followed in the preparation of the financial statements:

Cash and Cash Equivalents. Cash and cash equivalents include money market instruments with maturities of less than three months.

Portfolio Investment Valuations. Investments are stated at "fair value" as defined in the 1940 Act and in the applicable regulations of the Securities and Exchange Commission. All assets are valued at fair value as determined in good faith by, or under the direction of, the Board of Directors. See the Asset Valuation Policy Guidelines in the Footnote to Schedule of Investments.

Securities Transactions. Securities transactions are accounted for on the date the securities are purchased or sold (trade date); dividend income is recorded on the ex-dividend date; and interest income is accrued as earned. Realized gains and losses on investment transactions are determined on the first-in, first-out basis for financial reporting and tax basis.

Income Taxes. The Company records income taxes using the liability method in accordance with the provision of Statement of Financial Accounting Standards No. 109. Accordingly, deferred tax liabilities have been established to reflect temporary differences between the recognition of income and expenses for financial reporting and tax purposes, the most significant difference of which relates to the Company's unrealized appreciation on investments.

Reclassifications. Certain reclassifications have been made to the March 31, 1996 and December 31, 1996 financial statements to conform to the March 31, 1997 presentation.

Estimates by Management. The preparation of the financial statements in conformity with Generally Accepted Accounting Principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of March 31, 1997 and December 31,1996 and the reported amounts of revenues and expenses for the three months ended March 31, 1997 and March 31, 1996. Actual results could differ from these estimates.

16

NOTE 3. STOCK OPTION PLAN AND WARRANTS OUTSTANDING


On August 3, 1989, the shareholders of the Company approved the 1988 Long Term Incentive Compensation Plan. On June 30, 1994, the shareholders of the Company approved various amendments to the 1988 Long Term Incentive Compensation Plan: 1) to conform to the provisions of the Business Development Company regulations under the 1940 Act, which allow for the issuance of stock options to qualified participants; 2) to increase the reserved shares under the amended plan; 3) to call the plan the 1988 Stock Option Plan, as Amended and Restated (the "1988 Plan"); and 4) to make various other amendments. On October 20, 1995, the shareholders of the Company approved an amendment to the 1988 Plan authorizing automatic 20,000 share grants of non-qualified stock options to newly elected non-employee directors of the Company.

Under the 1988 Plan, the number of shares of common stock of the Company reserved for issuance is equal to 20 percent of the outstanding shares of common stock of the Company at the time of grant. However, so long as warrants, options, and rights issued to persons other than the Company's directors, officers, and employees at the time of grant remain outstanding, the number of reserved shares under the 1988 Plan may not exceed 15 percent of the outstanding shares of common stock of the Company at the time of grant, subject to certain adjustments.

The 1988 Plan provides for the issuance of incentive stock options and non-qualified stock options to eligible employees as determined by the Compensation Committee of the Board (the "Committee"), which is composed of four non-employee directors. The Committee also has the authority to construe

and interpret the 1988 Plan, to establish rules for the administration of the 1988 Plan and, subject to certain limitations, to amend the terms and conditions of any outstanding awards. Options may be exercised for up to 10 years from the date of grant at prices not less than the fair market value of the Company's common stock at the date of grant. The 1988 Plan provides that payment by the optionee upon exercise of an option may be made using cash or Company stock held by the optionee.

The Company accounts for the 1988 Plan under APB Opinion No. 25, under which no compensation cost has been recognized. Had compensation cost for the 1988 Plan been determined consistent with the fair value method required by FASB Statement No. 123 ("FASB No. 123"), the Company's net realized income (loss) and net asset value per share would have been reduced to the following pro forma amounts:



The fair value of each option grant is estimated on the date of grant using the Black-Scholes option pricing model with the following weighted average assumptions:

</TABLE>

Because the FASB No. 123 method of accounting has not been applied to options granted prior to January 1, 1995, the resulting pro forma compensation cost and related impact on net realized income (loss) and net asset value per share may not be representative of that value to be expected in future years.

The Company may grant options for up to 2,088,536 shares under the 1988 Plan. The Company has granted options on 1,180,000 shares and warrants on 237,605 shares through March 31, 1997. Under the 1988 Plan, the option exercise price equals the stock's market price on date of grant. The options granted vest over a five year period and expire after 10 years.

A summary of the status of the Company's 1988 Plan at March 31, 1997 and 1996 and changes during the three months then ended is presented in the table and narrative below:

<TABLE>

<s></s>	<c> <c> March 31, 1997</c></c>	<c> <c> March 31, 1996</c></c>
	Shares Weighted Average	d Shares Weighted Average
	Exercise Price	Exercise Price

Outstanding at

beginning of the period 1,080,000 \$4.58 1,050,000 \$4.44 Granted 300,000 \$3.87 60,000 \$6.18 Exercised - 50,000 \$1.75 Forfeited 200,000 \$5.37 - -

Expired

Outstanding at end of period 1,180,000 \$4.27 1,060,000 \$4.67 Exercisable at end of period 403,000 \$3.42 326,812 \$2.93

Weighted average fair value of

options granted \$2.50 - \$4.00

</TABLE>

The range of exercise prices for the outstanding options as of March 31, 1997 are: 8,000 options at \$1.1875, with a remaining life of 4.7 years; 150,000 options at \$1.625, with a remaining life of 2.3 years; 180,000 options at \$3.00 to \$3.75, with an average exercise price of \$3.375 and an average remaining life of 5.1 years; 542,000 options at \$5.375 to \$7.00, with an average exercise price of \$5.485 and an average remaining life of 8.4 years; 300,000 options at \$3.875, with a remaining life of 9.1 years.

As of March 31, 1997, there were outstanding warrants to purchase 237,605 shares of common stock at a price of \$2.0641 per share expiring in 1999.

18

NOTE 4. EMPLOYEE BENEFITS

As of August 15, 1990, the Company entered into a non-competition, employment and severance contract with its Chairman, Charles E. Harris, pursuant to which he is to receive compensation in the form of salary and other benefits. This contract was amended on June 30, 1992, January 3, 1993, and June 30, 1994. The term of the contract expires on December 31, 1999.

Base salary is to be increased annually to reflect inflation and in addition may be increased by such amount as the Compensation Committee of the Board of Directors of the Company deems appropriate. In addition, Mr. Harris would be entitled, under certain circumstances, to receive severance pay under the employment and severance contracts.

As of January 1, 1989, the Company adopted an employee benefits program covering substantially all employees of the Company under a 401(k) Plan and Trust Agreement. The Company's contribution to the plan are determined by the Compensation Committee in the fourth quarter.

On June 30, 1994, the Company adopted a plan to provide medical and health coverage for retirees, their spouses and dependents who, at the time of their retirement, have ten years of service with the Company and have attained 50 years of age or have attained 45 years of age and have 15 years of service with the Company. On February 10, 1997, the Company amended this plan to include employees who "have seven full years of service and have attained 58 years of age." The coverage is secondary to any government provided or subsequent employer provided health insurance plans. Based upon actuarial estimates, the Company provided an original reserve of \$176,520 that was charged to operations for the period ending June 30,1994. As of March 31, 1997,the Company had a reserve of \$232,415 for the plan.

NOTE 5. INCOME TAXES

The Company has not elected tax treatment available to regulated investment companies under Sub-Chapter M of the Internal Revenue Code. Accordingly, for federal and state income tax purposes, the Company is taxed at statutory corporate rates on its income, which enables the Company to offset any future net operating losses against prior years' net income. The Company may carry back operating losses against net income three years and carry forward such losses fifteen years.

19

For the three months ended March 31, 1997 and 1996, the Company's income tax (benefit) provision was allocated as follows:

<TABLE> $\langle S \rangle$ <C> <C> Three Three Months Ended Months Ended March 31, 1997 March 31, 1996 \$ (198,881) \$ (154,130) Investment operations Realized gain on investments 218,088 (Decrease) increase in unrealized appreciation on investments (911,479)428.118 Total income tax (benefit) provision \$ (892,272) \$ 296,535

The above tax (benefit) provision consists of the following:

 Current -- Federal
 \$ 16,197
 \$ (134,593)

 Deferred -- Federal
 (908,469)
 431,128

 Total income tax (benefit) provision
 \$ (892,272)
 \$ 296,535

The Company's deferred tax liability at March 31, 1997 and December 31, 1996 consists of the following:

March 31, 1997 December 31, 1996
Unrealized appreciation on investments \$ 1,384,519 \$ 2,295,998
Medical retirement benefits (81,345) (72,320)
Other (24,196) (36,231)

Net deferred income tax liability \$ 1,278,978 \$ 2,187,447

</TABLE>

The exercise of nonqualified stock options and certain warrants give rise to compensation which is includable in the taxable income of recipients and deductible by the Company for federal and state income tax purposes. Compensation resulting from increases in the fair market value of the Company's common stock subsequent to the date of grant of the applicable exercised stock options and warrants is not recognized, in accordance with Accounting Principles Board Opinion No.25, as an expense for financial accounting purposes.

NOTE 6. COMMITMENTS AND CONTINGENCIES

During 1993, the Company signed a ten-year lease with sublet provisions for office space. In 1995, this lease was amended to include additional office space. Rent expense under this lease was \$39,497 and \$38,346 for the three months ended March 31, 1997 and 1996, respectively. Future minimum lease payments in each of the following years are: 1998 -- \$168,768; 1999 -- \$176,030; 2000 -- \$178,561; 2001 --\$178,561; 2002 -- \$178,561; thereafter \$101,946.

20

The Company has guaranteed a three-year lease obligation of approximately \$21,000 per annum for the office space of one of its investees, Highline Capital Management LLC.

In December 1993, the Company and MIT announced the establishment by the Company of the Harris & Harris Group Senior Professorship at MIT. Prior to the arrangement for the establishment of this Professorship, the Company had made gifts of stock in start-up companies to MIT. These gifts, together with the contribution of \$700,000 in cash in 1993, which was expensed by the Company in 1993, were used to establish this named chair.

The Company contributed to MIT securities with a cost basis of \$3,280, \$20,000 and \$20,000 in 1993, 1994, and 1995 respectively. These contributions will be applied to the MIT Pledge at their market value at the time the shares become publicly traded or otherwise monetized in a commercial transaction and are free from restriction as to sale by MIT.

At December 31, 1996, the Company would have to fund additional cash and/or property that would have to be valued at a total of \$756,720 by

December 1998, in order for the Senior Professorship to become permanent.

In January 1997, the Company signed loan agreements with two of its investee companies for up to \$750,000. As of March 31, 1997, the Company had loaned \$350,000 to the investee companies. In addition, the Company has guaranteed a bonus of up to \$100,000 to the key employees of one of its investee companies.

21

Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations

Statement of Operations

The Company accounts for its operations under Generally Accepted Accounting Principles for investment companies. On this basis, the principal measure of its financial performance is captioned "Net (decrease) increase in net assets from operations," which is the sum of three elements. The first element is "Net operating loss," which is the difference between the Company's income from interest, dividends, and fees and its operating expenses, net of applicable income tax benefits. The second element is "Net realized gain on investments," which is the difference between the proceeds received from dispositions of portfolio securities and their stated cost, net of applicable income tax provisions (benefits). These two elements are combined in the Company's financial statements and reported as "Net realized income (loss)." The third element, "Net (decrease) increase in unrealized appreciation on investments," is the net change in the fair value of the Company's investment portfolio, net of increase (decrease) in deferred income taxes that would become payable if the unrealized appreciation were realized through the sale or other disposition of the investment portfolio.

"Net realized gain on investments" and "Net (decrease) increase in unrealized appreciation on investments" are directly related. When a security is sold to realize a gain (loss), net unrealized appreciation decreases (increases) and net realized gain increases (decreases).

Financial Condition

The Company's total assets and net assets were, respectively, \$36,365,277 and \$34,270,315 at March 31, 1997, versus \$38,555,290 and \$35,932,603 at December 31, 1996. Net asset value per share was \$3.28 at March 31, 1997, versus \$3.44 at December 31, 1996.

The Company's financial condition is dependent on the success of its investments. The Company has invested a substantial portion of its assets in private development stage or start-up companies. These private businesses tend to be thinly capitalized, unproven, small companies that lack management depth or have no history of operations. At March 31, 1997, 54.3 percent of the Company's \$36 million in total assets consisted of investments at fair value in private businesses, of which net unrealized appreciation was approximately \$4.2 million before taxes. At December 31, 1996, 48.8 percent of the Company's \$39 million in total assets consisted of investments at fair value in private businesses, of which net unrealized appreciation was approximately \$5 million before taxes.

22


A summary of the Company's investment portfolio is as follows: <TABLE>

<s> M</s>	<c> <c> arch 31, 1997 Dece</c></c>	mber 31, 1996
Investments, at cost Unrealized appreciation	\$ 29,640,161 4,063,364	\$ 28,981,093 6,667,589
Investments, at fair value	\$ 33,703,525	\$ 35,648,682
=		

 | |The accumulated unrealized appreciation on investments net of deferred taxes is \$2,678,845 at March 31, 1997, versus \$4,371,591 at December 31, 1996.

Following an initial investment in a private company, the Company may make additional investments in such investee in order to: (1) increase its ownership percentage; (2) to exercise warrants or options that were acquired in a prior financing; (3) to preserve the Company's proportionate ownership in a subsequent financing or (4) attempt to preserve or enhance the value of the Company's investment. Such additional investments are referred to as "follow-on" investments. There can be no assurance that the Company will make follow-on investments or have sufficient funds to make additional investments. The failure to make such follow-on investments could jeopardize the viability of the investee company and the Company's investment or could result in a missed opportunity for the Company to participate to a greater extent in an investee's successful operations. The Company attempts to maintain adequate liquid capital to make follow-on investments in its private investee portfolio companies. The Company may elect not to make a follow-on investment either because it does not want to increase its concentration of risk or because it prefers other opportunities, even though the follow-on investment opportunity appears attractive.

The following table is a summary of the cash investments made by the Company in its private placement portfolio during the three months ended March 31, 1997:



Results of Operations

Investment Income and Expenses:

The Company's principal objective is to achieve capital appreciation. Therefore, a significant portion of the investment portfolio is structured to maximize the potential for capital appreciation and provides little or no current yield in the form of dividends or interest. The Company does earn interest income from fixed-income securities, including U.S. Government Obligations. The amount of interest income earned varies based upon the average balance of the Company's fixed-income portfolio and the average yield on this portfolio.

The Company had interest income from fixed-income securities of \$136,287 and \$227,338 for the three months ended March 31,1997 and 1996 respectively. The decrease is a result of a decline in the balance of the Company's fixed-income portfolio. The Company also received consulting and administrative fees from certain portfolio companies which totaled \$869 for the three months ended March 31, 1997 and \$24,896 for the three months ended March 31, 1996.

Operating expenses were \$720,599 and \$709,610 for the three months ended March 31, 1997 and 1996, respectively. Most of the Company's operating expenses are related to employee and director compensation, office and rent

expenses and consulting and professional fees (primarily legal and accounting fees).

Net operating losses before taxes were \$573,443 and \$443,286 for the three months ended March 31, 1997 and 1996, respectively.

The Company has in the past relied, and continues to rely to a large extent, upon proceeds from sales of investments, rather than investment income, to defray a significant portion of its operating expenses. Because such sales cannot be predicted with certainty, the Company attempts to maintain adequate working capital to provide for fiscal periods when there are no such sales.

Realized Gains and Losses on Sales of Portfolio Securities:

During the three months ended March 31, 1997 and 1996, the Company sold various public securities realizing net gains of \$623,108 and \$64,420, respectively.

Unrealized Appreciation and Depreciation of Portfolio Securities:

Net unrealized appreciation on investments before taxes decreased \$2,604,225 during the three months ended March 31, 1997, from \$6,667,589 to \$4,063,364 owing primarily to decreased valuations for Harber Brothers Productions, Inc. and PureSpeech, Inc. and the realization of previously unrealized gains on public securities, offset by an increase in the valuation of PowerVoice Technologies, Inc.

Net unrealized appreciation on investments increased \$1,223,194 during the three months ended March 31, 1996, from \$2,102,593 to \$3,325,786, owing primarily to increased valuations for Princeton Video Image, Inc., PHZ Captal Partners and Alliance Pharmaceutical Corp., offset by the decreased valuation of Sonex International Corporation and Dynecology, Inc.

24

Liquidity and Capital Resources

The Company reported total cash, receivables and marketable securities (the primary measure of liquidity) at March 31, 1997 of \$16,317,105, versus \$19,296,591 at December 31, 1996. Management believes that its cash, receivables and marketable securities provide the Company with sufficient liquidity for its operations.

Risks

Pursuant to Section 64(b)(1) of the Investment Company Act of 1940, a Business Development Company is required to describe the risk factors involved in an investment in the securities of such company inherent in the nature of the company's investment portfolio. There are significant risks inherent in the Company's venture capital business. The Company has invested a substantial portion of its assets in private development stage or start-up companies. These private businesses tend to be thinly capitalized, unproven, small companies that lack management depth and have not attained profitability or have no history of operations. Because of the speculative nature and the lack of a public market for these investments, there is significantly greater risk of loss than is the case with traditional investment securities. The Company expects that some ofits venture capital investments will be a complete loss or will be unprofitable and that some will appear to be likely to become successful but never realize their potential. The Company has been risk seeking rather than risk averse in its approach to venture capital and other investments. Neither the Company's investments nor an investment in the Company is intended to constitute a balanced investment program. The Company does not currently pay or intend to pay cash dividends. The Company has in the past relied and continues to rely to a large extent upon proceeds from sales of investments rather than investment income to defray a significant portion of its operating expenses.

Item 1. Legal Proceedings None

Item 2. Changes in Securities

None

Item 3. Defaults Upon Senior Securities

Item 4. Submission of Matters to a Vote of Security Holders
None

Item 5. Other Information

None

Item 6. Exhibits and Reports on Form 8-K

- (a) See Exhibit Index for Exhibits to the Form 10-Q
- (b) None EXHIBIT INDEX

Item Number (of Item 601 of Regulation S-K)

27. Financial Data Schedule

26

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Harris & Harris Group, Inc.

2.7

Date: May 13, 1997

```
<ARTICLE> 6
<CIK> 0000893739
<NAME> HARRIS & HARRIS GROUP, INC.
<S>
                        <C>
<PERIOD-TYPE>
                              3-MOS
<FISCAL-YEAR-END>
                                 DEC-31-1996
                              MAR-31-1997
<PERIOD-END>
<INVESTMENTS-AT-COST>
                                    29,640,161
<INVESTMENTS-AT-VALUE>
                                     33,703,525
<RECEIVABLES>
                                2,210,186
<ASSETS-OTHER>
                                 292,444
                                       0
<OTHER-ITEMS-ASSETS>
<TOTAL-ASSETS>
                               36,365,277
<PAYABLE-FOR-SECURITIES>
                                         0
<SENIOR-LONG-TERM-DEBT>
<OTHER-ITEMS-LIABILITIES>
                                     2,094,962
<TOTAL-LIABILITIES>
                                  2,094,962
<SENIOR-EQUITY>
                                    0
<PAID-IN-CAPITAL-COMMON>
                                      5,850,576
<SHARES-COMMON-STOCK>
                                      10,442,682
<SHARES-COMMON-PRIOR>
                                     10,442,682
<ACCUMULATED-NII-CURRENT>
                                            0
<OVERDISTRIBUTION-NII>
                                        0
<ACCUMULATED-NET-GAINS>
                                       15,636,467
<OVERDISTRIBUTION-GAINS>
                                          0
<ACCUM-APPREC-OR-DEPREC>
                                       2,678,845
<NET-ASSETS>
                              34,270,315
<DIVIDEND-INCOME>
<INTEREST-INCOME>
                                   136,287
<OTHER-INCOME>
                                  10,869
                                 720,599
<EXPENSES-NET>
<NET-INVESTMENT-INCOME>
                                       (374,562)
<REALIZED-GAINS-CURRENT>
                                       405,020
<APPREC-INCREASE-CURRENT>
                                       (2,604,225)
<NET-CHANGE-FROM-OPS>
                                     (1,662,288)
<EQUALIZATION>
                                    0
<DISTRIBUTIONS-OF-INCOME>
                                          0
<DISTRIBUTIONS-OF-GAINS>
                                         0
<DISTRIBUTIONS-OTHER>
                                        0
<NUMBER-OF-SHARES-SOLD>
                                          0
<NUMBER-OF-SHARES-REDEEMED>
                                              0
                                       0
<SHARES-REINVESTED>
<NET-CHANGE-IN-ASSETS>
                                    (1,662,288)
<ACCUMULATED-NII-PRIOR>
                                         0
<ACCUMULATED-GAINS-PRIOR>
                                        15,606,009
<OVERDISTRIB-NII-PRIOR>
                                        0
<OVERDIST-NET-GAINS-PRIOR>
                                          0
<GROSS-ADVISORY-FEES>
                                        0
<INTEREST-EXPENSE>
                                      0
                                    0
<GROSS-EXPENSE>
<AVERAGE-NET-ASSETS>
                                    35,101,459
<PER-SHARE-NAV-BEGIN>
                                       3.44
<PER-SHARE-NII>
<PER-SHARE-GAIN-APPREC>
                                         0
<PER-SHARE-DIVIDEND>
                                       0
<PER-SHARE-DISTRIBUTIONS>
                                          0
<RETURNS-OF-CAPITAL>
                                       0
<PER-SHARE-NAV-END>
                                      3.28
                                    0
<EXPENSE-RATIO>
<AVG-DEBT-OUTSTANDING>
                                          0
                                        0
<AVG-DEBT-PER-SHARE>
```

<TABLE> <S> <C>